*European Journal of Pharmacology*, 230 (1993) 393–396
© 1993 Elsevier Science Publishers B.V. All rights reserved 0014-2999/93/$06.00


# Author index


Abi-Dargham, A., see Laruelle, M. (230) 119
Acquas, E., Meloni, M. and Di Chiara, G.
Blockade of δ-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release (230) 239
Agnati, L.F., see Martire, M. (230) 231
Al-Tikriti, M.S., see Laruelle, M. (230) 119
Allix, M., see Wahl, F. (230) 209
Altavilla, D., see Squadrito, F. (230) 125
Archer, S., see Jiang, Q. (230) 129
Artalejo, A.R., see Montiel, C. (230) 77
Attila, M., see Salvadori, S. (230) 357

Baeyens, J.M., see Ocaña, M. (230) 203
Baldwin, R.M., see Laruelle, M. (230) 119
Balster, R.L., see Gold, L.H. (230) 285
Barber, P.C., see Barnes, J.M. (230) 251
Bardgett, M.E., Wrona, C.T., Newcomer, J.W. and Csernansky, J.G.
Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics (230) 245
Barnes, J.M., Steward, L.J., Barber, P.C. and Barnes, N.M.
Identification and characterisation of angiotensin II receptor subtypes in human brain (230) 251
Barnes, N.M., see Barnes, J.M. (230) 251
Bax, W.A., see Schoemaker, R.G. (230) 103
Beani, L., see Tanganelli, S. (230) 159
Bernard, J.-F., see Huang, G.-F. (230) 279
Bervoets, K., see Millan, M.J. (230) 99
Besson, J.-M., see Huang, G.-F. (230) 279
Bianchi, C., see Tanganelli, S. (230) 159
Bidlack, J.M., see Jiang, Q. (230) 129
Bonnet, J.-J., see Vaugeois, J.-M. (230) 195
Bos, E., see Schoemaker, R.G. (230) 103
Boulu, R.G., see Wahl, F. (230) 209
Bourinbaiar, A.S. and Nagorny, R.
Inhibitory effect of natural interferon alpha on human immunodeficiency virus type 1 transmission from epithelial cells to lymphocytes in vitro (230) 15
Briley, M., see Moret, C. (230) 379
Brocco, M., see Millan, M.J. (230) 99
Brown, C.A., see Chan, S.L.F. (230) 375
Bryant, S.D., see Salvadori, S. (230) 357
Budihna, M.V. and Strojan, P.
$Ca^{2+}$ channel antagonists inhibit the intestinal absorption of digoxin in the guinea-pig (230) 301
Bundy, D.M., see Salvadori, S. (230) 357
Burnstock, G., see Rennick, R.E. (230) 367

Calapai, G., see Squadrito, F. (230) 125
Campo, G.M., see Squadrito, F. (230) 125
Canton, H., see Millan, M.J. (230) 99
Caputi, A.P., see Squadrito, F. (230) 125
Chan, S.L.F., Brown, C.A. and Morgan, N.G.
Stimulation of insulin secretion by the imidazoline $\alpha_2$-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site (230) 375
Charney, D.S., see Laruelle, M. (230) 119
Cheng, P.Y., Wu, D., Decena, J., Soong, Y., McCabe, S. and Szeto, H.H.
Opioid-induced stimulation of fetal respiratory activity by [D-Ala$^2$]deltorphin I (230) 85
Chiba, S., see Skrbic, R. (230) 131
Chiodo, L.A., see Zhang, J. (230) 371
Costentin, J., see Vaugeois, J.-M. (230) 195
Csernansky, J.G., see Bardgett, M.E. (230) 245
Cucinotta, D., see Squadrito, F. (230) 125

Daniel, E.E., see Low, A.M. (230) 53
Darby, P.J., see Low, A.M. (230) 53
Decena, J., see Cheng, P.Y. (230) 85
Delbro, D.S., see Gustafsson, B.I. (230) 1
Del Pozo, E., see Ocaña, M. (230) 203
De Sarro, A., see De Sarro, G. (230) 151
De Sarro, G., Donato Di Paola, E., De Sarro, A. and Vidal, M.J.
L-Arginine potentiates excitatory amino acid-induced seizures elicited in the deep prepiriform cortex (230) 151
Diana, M., Pistis, M., Muntoni, A. and Gessa, G.
Heterogeneous responses of substantia nigra pars reticulata neurons to γ-hydroxybutyric acid administration (230) 363
Di Chiara, G., see Acquas, E. (230) 239
Donato Di Paola, E., see De Sarro, G. (230) 151
Du, X.Y., see Schoemaker, R.G. (230) 103
Dunn, P.M.
Ganglion-blocking activity of dequalinium in frog and rat sympathetic ganglia in vitro (230) 335
Duterte-Boucher, D., see Vaugeois, J.-M. (230) 195
Dyer, D.C., see Zhang, L. (230) 115

Ebert, B., see Madsen, U. (230) 383
Eikenburg, D.C., see Lakhlani, P.P. (230) 107
Endo, C., see Okawa, T. (230) 341

Ferraro, L., see Tanganelli, S. (230) 159
Finta, E.P., see Sevcik, J. (230) 223
Fournié-Zaluski, M.-C., see Noble, F. (230) 139
Freeman, A.S., see Zhang, J. (230) 371
Frost, J.J., see Laruelle, M. (230) 119
Fujita, K., see Matsumura, Y. (230) 89
Fuxe, K., see Martire, M. (230) 231
Fuxe, K., see Tanganelli, S. (230) 159

Galligan, J.J., see Minocha, A. (230) 187
García, A.G., see Montiel, C. (230) 77
Gessa, G., see Diana, M. (230) 363
Gibb, W.R.G., see Rose, S. (230) 177
Gobert, A., see Millan, M.J. (230) 99
Gold, L.H. and Balster, R.L.
Effects of NMDA receptor antagonists in squirrel monkeys trained to discriminate the competitive NMDA receptor antagonist NPC 12626 from saline (230) 285
Grahame-Smith, D., see Grasby, P. (230) 41
Grahame-Smith, D.G., see Pei, Q. (230) 63

Grasby, P., Sharp, T., Moorman, J. and Grahame-Smith, D.
Comparison of the effect of buspirone and 1-(2-Pyrimidinyl)-piperazine on cerebral glucose utilization in the rat (230) 41
Gulati, A. and Srimal, R.C.
Endothelin antagonizes the hypotension and potentiates the hypertension induced by clonidine (230) 293
Gustafsson, B.I. and Delbro, D.S.
Motor effects of indomethacin, morphine or vagal nerve stimulation on the feline small intestine in vivo (230) 1

Hamra, M. and Rosen, M.R.
The influence of pH on the use-dependent effects of lidocaine in adult and neonatal canine Purkinje fibers (230) 167
Hansen, J.J., see Madsen, U. (230) 383
Hawley, S.B., see Woodward, D.F. (230) 327
Hiramatsu, M., see Ishihara, S.-i. (230) 313
Hoffer, P.B., see Laruelle, M. (230) 119
Hoshi, K., see Okawa, T. (230) 341
Hu, S. and Kim, H.S.
Activation of $K^+$ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid (230) 215
Huang, G.-F., Besson, J.-M. and Bernard, J.-F.
Morphine depresses the transmission of noxious messages in the spino(trigemino)-ponto-amygdaloid pathway (230) 279
Hušek, P., see Šmíd, M. (230) 69

Ikeda, M., see Kihara, T. (230) 271
Illes, P., see Sevcik, J. (230) 223
Innis, R.B., see Laruelle, M. (230) 119
Ioculano, M., see Squadrito, F. (230) 125
Ishihara, S.-i., Hiramatsu, M., Kameyama, T. and Nabeshima, T.
Development of tolerance to amnesic effects of chlordiazepoxide in relation to GABAergic and cholinergic neuronal systems (230) 313
Itzhak, Y.
Repeated methamphetamine-treatment alters brain $\sigma$ receptors (230) 243

Jackson, E.A., see Rose, S. (230) 177
Jaehnig, P., see Rose, S. (230) 177
Jenner, P., see Rose, S. (230) 177
Jiang, Q., Sebastian, A., Archer, S. and Bidlack, J.M.
5$\beta$-Methyl-14$\beta$-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting $\mu$-opioid receptor antagonist devoid of agonist properties (230) 129
Johns, E.J.
Effect of BRL 38227 on the adrenergic regulation of the kidney vasculature of the rat (230) 47

Kalant, H., see Khanna, J.M. (230) 23
Kameyama, T., see Ishihara, S.-i. (230) 313
Khanna, J.M., Shah, G., Weiner, J., Wu, P.H. and Kalant, H.
Effect of NMDA receptor antagonists on rapid tolerance to ethanol (230) 23
Kihara, T., Ikeda, M., Matsubara, K. and Matsushita, A.
Differential effects of ceruletide on amphetamine-induced behaviors and regional dopamine release in the rat (230) 271
Kim, H.S., see Hu, S. (230) 215
Korpi, E.R., see Taira, T. (230) 307
Krogsgaard-Larsen, P., see Madsen, U. (230) 383
Kromer, W.
Synergistic opioid inhibition of colonic $Cl^-$ secretion by $\kappa$-opioid receptor agonism plus $\mu$-opioid receptor antagonism (230) 235
Kwan, C.-Y., see Low, A.M. (230) 53

Lakhlani, P.P. and Eikenburg, D.C.
Dependence of prejunctional $\beta$-adrenoceptor facilitation of sympathetic neurotransmission on stimulus train length and agonist exposure time (230) 107
Laruelle, M., Abi-Dargham, A., Rattner, Z., Al-Tikriti, M.S., Zea-Ponce, Y., Zoghbi, S.S., Charney, D.S., Price, J., Frost, J.J., Hoffer, P.B., Baldwin, R.M. and Innis, R.B.
Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [$^{123}$I]iomazenil (230) 119
Lazarus, L.H., see Salvadori, S. (230) 357
Lejeune, F., see Millan, M.J. (230) 99
Leslie, R.A., see Pei, Q. (230) 63
Li, X.-M., see Tanganelli, S. (230) 159
Low, A.M., Darby, P.J., Kwan, C.-Y. and Daniel, E.E.
Effects of thapsigargin and ryanodine on vascular contractility: cross-talk between sarcoplasmic reticulum and plasmalemma (230) 53

Madsen, U., Ebert, B., Hansen, J.J. and Krogsgaard-Larsen, P.
The non-depolarizing D-form of bromohomoibotenic acid enhances depolarizations evoked by the L-form or quisqualate (230) 383
Marsden, C.D., see Rose, S. (230) 177
Martire, M., Pistritto, G., Mores, N., Agnati, L.F. and Fuxe, K.
Region-specific inhibition of potassium-evoked [$^3$H]noradrenaline release from rat brain synaptosomes by neuropeptide Y-(13–36). Involvement of NPY receptors of the $Y_2$ type (230) 231
Matsubara, K., see Kihara, T. (230) 271
Matsumura, Y., Fujita, K., Takaoka, M. and Morimoto, S.
Big endothelin-3-induced hypertension and its inhibition by phosphoramidon in anaesthetized rats (230) 89
Matsushita, A., see Kihara, T. (230) 271
McCabe, S., see Cheng, P.Y. (230) 85
McLean, M.J., see Wamil, A.W. (230) 263
Meloni, M., see Acquas, E. (230) 239
Millan, M.J., Rivet, J.-M., Canton, H., Lejeune, F., Gobert, A., Widdowson, P., Bervoets, K., Brocco, M. and Peglion, J.-L.
S 15535: a highly selective benzodioxopiperazine 5-$HT_{1A}$ receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively (230) 99
Milner, P., see Rennick, R.E. (230) 367
Minocha, A. and Galligan, J.J.
Excitatory and inhibitory responses mediated by $GABA_A$ and $GABA_B$ receptors in guinea pig distal colon (230) 187
Montiel, C., Artalejo, A.R., Sánchez-García, P. and García, A.G.
Two components in the adrenal nicotinic secretory response revealed by cobalt ramps (230) 77
Moorman, J., see Grasby, P. (230) 41
Mores, N., see Martire, M. (230) 231
Moret, C. and Briley, M.
Does 5-carboxamidotryptamine-induced turning in guinea-pigs involve 5-$HT_{1D}$ autoreceptors? (230) 379
Morgan, N.G., see Chan, S.L.F. (230) 375
Morimoto, S., see Matsumura, Y. (230) 89
Mulder, A.H., see Ronken, E. (230) 349
Muntoni, A., see Diana, M. (230) 363

Nabeshima, T., see Ishihara, S.-i. (230) 313
Nagorny, R., see Bourinbaiar, A.S. (230) 15
Nakanishi, H., see Okawa, T. (230) 341
Newcomer, J.W., see Bardgett, M.E. (230) 245
Nieves, A.L., see Woodward, D.F. (230) 327
Noble, F., Fournié-Zaluski, M.-C. and Roques, B.P.
Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice (230) 139
Nomoto, M., see Rose, S. (230) 177

Ocaña, M., Del Pozo, E. and Baeyens, J.M.
ATP-dependent $K^+$ channel blockers antagonize morphine- but not U-504,88H-induced antinociception (230) 203
O'Connor, W.T., see Tanganelli, S. (230) 159
Okawa, T., Suzuki, Y., Endo, C., Hoshi, K., Sato, A. and Nakanishi, H.
The influence of prostaglandins on the contractile response to electrical field stimulation in rabbit myometrial and cervical smooth muscles (230) 341

Patsalos, P.N., see Semba, J. (230) 321
Peglion, J.-L., see Millan, M.J. (230) 99
Pei, Q., Zetterström, T., Leslie, R.A. and Grahame-Smith, D.G.
5-$HT_3$ receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat (230) 63
Pfaffendorf, M., see Zhang, J. (230) 95
Pistis, M., see Diana, M. (230) 363
Pistritto, G., see Martire, M. (230) 231
Plotkine, M., see Wahl, F. (230) 209
Price, J., see Laruelle, M. (230) 119
Protzman, C.E., see Woodward, D.F. (230) 327

Rattner, Z., see Laruelle, M. (230) 119
Rennick, R.E., Milner, P. and Burnstock, G.
Thrombin stimulates release of endothelin and vasopressin, but not substance P, from isolated rabbit tracheal epithelial cells (230) 367
Rivet, J.-M., see Millan, M.J. (230) 99
Ronken, E., Van Muiswinkel, F.L., Mulder, A.H. and Schoffelmeer, A.N.M.
Opioid receptor-mediated inhibition of evoked catecholamine release from cultured neurons of rat ventral mesencephalon and locus coeruleus (230) 349
Roques, B.P., see Noble, F. (230) 139
Rose, S., Nomoto, M., Jackson, E.A., Gibb, W.R.G., Jaehnig, P., Jenner, P. and Marsden, C.D.
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets (230) 177
Rosen, M.R., see Hamra, M. (230) 167
Rudolf, G. and Wioland, N.
Acute blockade of dopamine receptors with haloperidol: a retinal model to study impairments of dopaminergic transmission (230) 259

Salvadori, S., Bryant, S.D., Temussi, P.A., Bundy, D.M., Attila, M., Tomatis, R. and Lazarus, L.H.
Relationship between receptor affinity and topography of N-terminally extended and bridged [$Tyr^1 \rightarrow Asp^4$]deltorphin C analogues: novel probes for the $\delta$-opioid receptor (230) 357
Sánchez-García, P., see Montiel, C. (230) 77
Sardella, A., see Squadrito, F. (230) 125
Sato, A., see Okawa, T. (230) 341
Saxena, P.R., see Schoemaker, R.G. (230) 103
Schade, F.U. and Schudt, C.
The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages (230) 9
Schoemaker, R.G., Du, X.Y., Bax, W.A., Bos, E. and Saxena, P.R.
5-Hydroxytryptamine stimulates human isolated atrium but not ventricle (230) 103
Schoffelmeer, A.N.M., see Ronken, E. (230) 349
Schudt, C., see Schade, F.U. (230) 9
Sebastian, A., see Jiang, Q. (230) 129
Semba, J. and Patsalos, P.N.
Milacemide effects on the temporal inter-relationship of amino acids and monoamine metabolites in rat cerebrospinal fluid (230) 321
Sevcik, J., Finta, E.P. and Illes, P.
Galanin receptors inhibit the spontaneous firing of locus coeruleus neurones and interact with $\mu$-opioid receptors (230) 223
Shah, G., see Khanna, J.M. (230) 23
Shalmi, M. and Thomsen, K.
Inhibition of tubular lithium reabsorption by amiloride in the conscious sodium-restricted rat (230) 33
Sharp, T., see Grasby, P. (230) 41
Short, K.R. and Tabakoff, B.
Chronic barbiturate treatment increases NMDA receptors but decreases kainate receptors in mouse cortex (230) 111
Skrbic, R. and Chiba, S.
Dominant antagonistic action of $\alpha_2$-adrenoceptor agonists on $\alpha_1$-agonist-induced vasoconstriction (230) 131
Šmíd, M. and Hušek, P.
Vasoconstrictor reaction to prostaglandins $E_1$ and $E_2$ in the isolated rat hindlimb mediated through serotonin release (230) 69
Soong, Y., see Cheng, P.Y. (230) 85
Spada, C.S., see Woodward, D.F. (230) 327
Squadrito, F., Calapai, G., Cucinotta, D., Altavilla, D., Zingarelli, B., Ioculano, M., Urna, G., Sardella, A., Campo, G.M. and Caputi, A.P.
Anorectic activity of $N^G$-nitro-L-arginine, an inhibitor of brain nitric oxide synthase, in obese Zucker rats (230) 125
Srimal, R.C., see Gulati, A. (230) 293
Steward, L.J., see Barnes, J.M. (230) 251
Strojan, P., see Budihna, M.V. (230) 301
Suzuki, Y., see Okawa, T. (230) 341
Szeto, H.H., see Cheng, P.Y. (230) 85

Tabakoff, B., see Short, K.R. (230) 111
Taira, T., Uusi-Oukari, M. and Korpi, E.R.
Early postnatal treatment with muscimol transiently alters brain $GABA_A$ receptors and open-field behavior in rat (230) 307
Takaoka, M., see Matsumura, Y. (230) 89
Tanganelli, S., Li, X.-M., Ferraro, L., Von Euler, G., O'Connor, W.T., Bianchi, C., Beani, L. and Fuxe, K.
Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine $D_2$ receptor affinity in rat neostriatum (230) 159
Temussi, P.A., see Salvadori, S. (230) 357
Thomsen, K., see Shalmi, M. (230) 33
Tomatis, R., see Salvadori, S. (230) 357

Urna, G., see Squadrito, F. (230) 125
Uusi-Oukari, M., see Taira, T. (230) 307

Van Meel, J.C.A., see Zhang, J. (230) 95
Van Muiswinkel, F.L., see Ronken, E. (230) 349
Van Zwieten, P.A., see Zhang, J. (230) 95
Vaugeois, J.-M., Bonnet, J.-J., Duterte-Boucher, D. and Costentin, J.
In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion (230) 195
Vidal, M.J., see De Sarro, G. (230) 151
Von Euler, G., see Tanganelli, S. (230) 159

Wahl, F., Allix, M., Plotkine, M. and Boulu, R.G.
Effect of riluzole on focal cerebral ischemia in rats (230) 209
Wamil, A.W. and McLean, M.J.
Effect of temperature on limitation by MK-801 of firing of action potentials by spinal cord neurons in cell culture (230) 263
Weiner, J., see Khanna, J.M. (230) 23
Widdowson, P., see Millan, M.J. (230) 99
Williams, L.S., see Woodward, D.F. (230) 327

Wioland, N., see Rudolf, G. (230) 259
Woodward, D.F., Spada, C.S., Hawley, S.B., Williams, L.S., Protzman, C.E. and Nieves, A.L.
Further studies on ocular responses to DP receptor stimulation (230) 327
Wrona, C.T., see Bardgett, M.E. (230) 245
Wu, D., see Cheng, P.Y. (230) 85
Wu, P.H., see Khanna, J.M. (230) 23

Zea-Ponce, Y., see Laruelle, M. (230) 119
Zetterström, T., see Pei, Q. (230) 63
Zhang, J., Chiodo, L.A. and Freeman, A.S.
Effects of phencyclidine, MK-801 and 1,3-di(2-tolyl)guanidine on non-dopaminergic midbrain neurons (230) 371
Zhang, J., Van Meel, J.C.A., Pfaffendorf, M. and Van Zwieten, P.A.
Cholera toxin but not pertussis toxin inhibits angiotensin II-enhanced contractions in the rat portal vein (230) 95
Zhang, L. and Dyer, D.C.
Lysergic acid diethylamide is a partial agonist at 5-$HT_2$ receptors in ovine uterine artery of late pregnancy (230) 115
Zingarelli, B., see Squadrito, F. (230) 125
Zoghbi, S.S., see Laruelle, M. (230) 119

*European Journal of Pharmacology*, 230 (1993) 397–406

© 1993 Elsevier Science Publishers B.V. All rights reserved 0014-2999/93/$06.00

# Key word index

**Acetylcholine receptors**
Chlordiazepoxide; Passive avoidance response; $GABA_A$/benzodiazepine receptors; Autoradiography; Tolerance (Ishihara, S.-i. (230) 313)

**Acidosis**
Lidocaine; Use dependence; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (230) 167)

**Addiction**
RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Conditioned place preference; Naloxone; (Mouse) (Noble, F. (230) 139)

**Adrenal medulla**
Cobalt ramps; Nicotinic receptors; Catecholamine secretion (Montiel, C. (230) 77)

**Adrenoceptor agonists**
$K^+$ channel activators; Renal haemodynamics; Renal nerve stimulation (Johns, E.J. (230) 47)

**$\alpha_1$-Adrenoceptors**
Lingual arteries (isolated); $\alpha_2$-Adrenoceptors; Phenylephrine; (Partial agonist) (Skrbic, R. (230) 131)

**$\alpha_2$-Adrenoceptors**
Lingual arteries (isolated); $\alpha_1$-Adrenoceptors; Phenylephrine; (Partial agonist) (Skrbic, R. (230) 131)

Islets of Langerhans; $K^+$ channels; Imidazoline; RX851033; RX851034; RX821002 (Chan, S.L.F. (230) 375)

**$\beta$-Adrenoceptors**
Desensitization; Facilitation; Prejunctional; Stimulus train length (Lakhlani, P.P. (230) 107)

**Age**
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Substantia nigra; Motor deficits; Dopamine; (Common marmoset) (Rose, S. (230) 177)

**AIDS**
Cytokine; T lymphocytes; Mucosa; Virus infection (Bourinbaiar, A.S. (230) 15)

**Amiloride**
$Li^+$ reabsorption; $Na^+$ restriction; $Li^+$ clearance (Shalmi, M. (230) 33)

**Amino acids**
Milacemide; Monoamine metabolites; Taurine; Homovanillic acid (HVA); Cerebrospinal fluid (Semba, J. (230) 321)

**cAMP**
Cytokines; Leukotrienes; Endotoxin (Schade, F.U. (230) 9)

**Amphetamine**
Ceruletide; Hyperlocomotion; Stereotypy; Microdialysis; (Rat) (Kihara, T. (230) 271)

**Analgesia**
Opioids; Parabrachial; Noxious; Thermal stimuli; Pain pathway; (Rat) (Huang, G.-F. (230) 279)

**Angiotensin II**
Cholera toxin; Pertussis toxin; Portal vein (rat); Dibutyryl cAMP (Zhang, J. (230) 95)

**[$^{125}$I]angiotensin II**
Angiotensin II receptor subtypes; Cerebellum (human); Substantia nigra (human); Brain (human); Losartan; PD123177 (Barnes, J.M. (230) 251)

**Angiotensin II receptor subtypes**
Cerebellum (human); Substantia nigra (human); Brain (human); [$^{125}$I]angiotensin II; Losartan; PD123177 (Barnes, J.M. (230) 251)

**Antinociception**
Opioid receptor antagonists; $\mu$-Opioid receptors (Jiang, Q. (230) 129)

Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Opiates (Ocaña, M. (230) 203)

**L-AP4 (L-2-amino-4-phosphonobutanoic acid)**
Excitatory amino acids; Sensitization; Quisqualate priming; Cortical wedge (Madsen, U. (230) 383)

**Arachidonic acid**
Cytochrome P450 epoxygenase; Epoxyeicosatrienoic acid; Patch-clamp method; $K^+$ channels ($Ca^{2+}$-activated); $K^+$ channel openers (Hu, S. (230) 215)

**L-Arginine**
Seizures; Nitric oxide (NO); Prepiriform cortex (deep); Excitatory amino acid; Sodium nitroprusside (De Sarro, G. (230) 151)

**Atrium**
Contractile force; Heart; 5-HT (5-hydroxytryptamine, serotonin); Ventricle; (Human) (Schoemaker, R.G. (230) 103)

**Autoradiography**
Chlordiazepoxide; Passive avoidance response; $GABA_A$/benzodiazepine receptors; Acetylcholine receptors; Tolerance (Ishihara, S.-i. (230) 313)

**Benzodiazepine receptors**
SPECT (single photon emission tomography); [$^{123}$I]Iomazenil (Laruelle, M. (230) 119)

**Big endothelin-3**
Endothelin-3; Hypertensive effect; Phosphoramidon; Metalloproteinase; (Conversion) (Matsumura, Y. (230) 89)

**Blood pressure**
Endothelin; Clonidine; Heart rate; Medulla (ventral surface); (Sprague-Dawley rat) (Gulati, A. (230) 293)

**BMY 7378**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; Raphe; S 15535; NAN-190; Spiperone (Millan, M.J. (230) 99)

**Brain**
Phenobarbital; Dependence; Glutamate receptors (Short, K.R. (230) 111)

Nitric oxide (NO); Food intake; Zucker rat (Squadrito, F. (230) 125)

NPY receptors; Terminals; [$^3$H]Noradrenaline release; (Rat) (Martire, M. (230) 231)

**Brain (human)**
Angiotensin II receptor subtypes; Cerebellum (human); Substantia nigra (human); [$^{125}$I]angiotensin II; Losartan; PD123177 (Barnes, J.M. (230) 251)

**Buspirone**
Glucose utilization; Hippocampus; Lateral habenular nucleus; 1-PP (1-(2-pyrimidinyl)-piperazine); 2-Deoxyglucose (Grasby, P. (230) 41)

**$Ca^{2+}$ channel blockers**
Digoxin; Intestinal absorption; (Guinea-pig) (Budihna, M.V. (230) 301)

**$Ca^{2+}$ mobilization**
Thapsigargin; Ryanodine; Smooth muscle (vascular) (Low, A.M. (230) 53)

**5-Carboxamidotryptamine**
5-$HT_{1D}$ receptors; Turning model; (Autoreceptor) (Moret, C. (230) 379)

**Catecholamine secretion**
Cobalt ramps; Nicotinic receptors; Adrenal medulla (Montiel, C. (230) 77)

**CCK-8 (cholecystokinin-8)**
Neurotensin; Receptor–receptor interaction; Dopamine $D_2$ receptors; Microdialysis; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

**Cerebellum (human)**
Angiotensin II receptor subtypes; Substantia nigra (human); Brain (human); [$^{125}$I]angiotensin II; Losartan; PD123177 (Barnes, J.M. (230) 251)

**Cerebral ischemia (focal)**
Riluzole; Neurological examination; Passive avoidance task; (Rat) (Wahl, F. (230) 209)

**Cerebrospinal fluid**
Milacemide; Amino acids; Monoamine metabolites; Taurine; Homovanillic acid (HVA) (Semba, J. (230) 321)

**Ceruletide**
Amphetamine; Hyperlocomotion; Stereotypy; Microdialysis; (Rat) (Kihara, T. (230) 271)

**Cervical smooth muscle**
Myometrium; Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$); Pregnancy; Electrical field stimulation (Okawa, T. (230) 341)

**CGP 37849**
Drug discrimination; NMDA receptor antagonists; NPC 12626; CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

**Chlordiazepoxide**
Passive avoidance response; $GABA_A$/benzodiazepine receptors; Acetylcholine receptors; Autoradiography; Tolerance (Ishihara, S.-i. (230) 313)

**Cholera toxin**
Angiotensin II; Pertussis toxin; Portal vein (rat); Dibutyryl cAMP (Zhang, J. (230) 95)

**Clonidine**
Endothelin; Blood pressure; Heart rate; Medulla (ventral surface); (Sprague-Dawley rat) (Gulati, A. (230) 293)

**$Cl^-$ secretion (intestinal)**
Opioids; Receptor subtypes (Kromer, W. (230) 235)

**Cobalt ramps**
Nicotinic receptors; Adrenal medulla; Catecholamine secretion (Montiel, C. (230) 77)

**Computer modelling**
Deltorphin; Opioid receptors; Peptide synthesis (Salvadori, S. (230) 357)

**Conditioned place preference**
RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Naloxone; Addiction; (Mouse) (Noble, F. (230) 139)

**Contractile force**
Atrium; Heart; 5-HT (5-hydroxytryptamine, serotonin); Ventricle; (Human) (Schoemaker, R.G. (230) 103)

**Corpus striatum**
Glutamate; Dopamine; Neuroleptics; Nucleus accumbens; (Rat) (Bardgett, M.E. (230) 245)

**Cortical wedge**
Excitatory amino acids; Sensitization; Quisqualate priming; L-AP4 (L-2-amino-4-phosphonobutanoic acid) (Madsen, U. (230) 383)

**CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid)**
Drug discrimination; NMDA receptor antagonists; NPC 12626; CGP 37849; Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

**Cytochrome P450**
Dopamine uptake inhibitors; [$^3$H]GBR 12783 binding site occupancy; Locomotor activity; (Mouse) (Vaugeois, J.-M. (230) 195)

**Cytochrome P450 epoxygenase**
Arachidonic acid; Epoxyeicosatrienoic acid; Patch-clamp method; $K^+$ channels ($Ca^{2+}$-activated); $K^+$ channel openers (Hu, S. (230) 215)

**Cytokine**
AIDS; T lymphocytes; Mucosa; Virus infection (Bourinbaiar, A.S. (230) 15)

**Cytokines**
Leukotrienes; Endotoxin; cAMP (Schade, F.U. (230) 9)

**Deltorphin**
Opioid receptors; Peptide synthesis; Computer modelling (Salvadori, S. (230) 357)

**[D-Ala$^2$]deltorphin**
Fetal breathing; Opiates; $\delta$-Opioid receptors; Naltrindole; Naloxonazine (Cheng, P.Y. (230) 85)

**2-Deoxyglucose**
Buspirone; Glucose utilization; Hippocampus; Lateral habenular nucleus; 1-PP (1-(2-pyrimidinyl)-piperazine) (Grasby, P. (230) 41)

**Dependence**
Phenobarbital; Glutamate receptors; Brain (Short, K.R. (230) 111)

**Dequalinium**
Sympathetic ganglia; Ganglion blockers; Muscarinic receptor antagonists; Nicotinic receptor antagonists (Dunn, P.M. (230) 335)

**Desensitization**
$\beta$-Adrenoceptors; Facilitation; Prejunctional; Stimulus train length (Lakhlani, P.P. (230) 107)

**Development**
Ethanol; Flunitrazepam; $GABA_A$ receptors; Muscimol; Ro 15-4513 (Taira, T. (230) 307)

**Dibutyryl cAMP**
Angiotensin II; Cholera toxin; Pertussis toxin; Portal vein (rat) (Zhang, J. (230) 95)

**Digoxin**
Intestinal absorption; $Ca^{2+}$ channel blockers; (Guinea-pig) (Budihna, M.V. (230) 301)

**Dissociation constant**
LSD (d-lysergic acid diethylamide); 5-HT receptors; Uterine artery (sheep) (Zhang, L. (230) 115)

**Distal colon**
Enteric nerves; GABA receptors; Gastrointestinal motility (Minocha, A. (230) 187)

**Dizocilpine**
Drug discrimination; NMDA receptor antagonists; NPC 12626; CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); CGP 37849; (Squirrel monkey) (Gold, L.H. (230) 285)

NMDA receptor antagonists; Phencyclidine; $\sigma$ Receptor ligands; Interneurons (Zhang, J. (230) 371)

**Dopamine**
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Substantia nigra; Motor deficits; Age; (Common marmoset) (Rose, S. (230) 177)

$\delta$-Opioid receptors; Ethanol (Acquas, E. (230) 239)

Glutamate; Neuroleptics; Nucleus accumbens; Corpus striatum; (Rat) (Bardgett, M.E. (230) 245)

Electrooculogram; Haloperidol; Light peak; Transepithelial potential; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Dopamine $D_2$ receptors**
Neurotensin; CCK-8 (cholecystokinin-8); Receptor–receptor interaction; Microdialysis; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

**Dopaminergic neurons**
$\gamma$-Hydroxybutyric acid (GHB); $GABA_A$ receptors; Ethanol; NMDA receptor antagonists (Diana, M. (230) 363)

**Dopamine uptake inhibitors**
[$^3$H]GBR 12783 binding site occupancy; Locomotor activity; Cytochrome P450; (Mouse) (Vaugeois, J.-M. (230) 195)

**DP receptors**
Eye; Inflammation; Intraocular pressure; Eosinophils; Prostaglandin $D_2$ (Woodward, D.F. (230) 327)

**Drug discrimination**
NMDA receptor antagonists; NPC 12626; CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); CGP 37849; Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

**Electrical field stimulation**
Myometrium; Cervical smooth muscle; Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$); Pregnancy (Okawa, T. (230) 341)

**Electrooculogram**
Dopamine; Haloperidol; Light peak; Transepithelial potential; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Electrophysiology (developmental)**
Lidocaine; Use dependence; Acidosis; Purkinje fibers (Hamra, M. (230) 167)

**Endothelin-3**
Big endothelin-3; Hypertensive effect; Phosphoramidon; Metalloproteinase; (Conversion) (Matsumura, Y. (230) 89)

Clonidine; Blood pressure; Heart rate; Medulla (ventral surface); (Sprague-Dawley rat) (Gulati, A. (230) 293)

Tracheal epithelium; Thrombin; Vasopressin; Substance P (Rennick, R.E. (230) 367)

**Endotoxin**
Cytokines; Leukotrienes; cAMP (Schade, F.U. (230) 9)

**Enteric nerves**
Distal colon; GABA receptors; Gastrointestinal motility (Minocha, A. (230) 187)

**Eosinophils**
Eye; Inflammation; Intraocular pressure; Prostaglandin $D_2$; DP receptors (Woodward, D.F. (230) 327)

**Epoxyeicosatrienoic acid**
Arachidonic acid; Cytochrome P450 epoxygenase; Patch-clamp method; $K^+$ channels ($Ca^{2+}$-activated); $K^+$ channel openers (Hu, S. (230) 215)

**Ethanol**
$\delta$-Opioid receptors; Dopamine (Acquas, E. (230) 239)

Development; Flunitrazepam; $GABA_A$ receptors; Muscimol; Ro 15-4513 (Taira, T. (230) 307)

$\gamma$-Hydroxybutyric acid (GHB); $GABA_A$ receptors; Dopaminergic neurons; NMDA receptor antagonists (Diana, M. (230) 363)

**Ethanol tolerance**
(+)-MK-801; Ketamine; NMDA receptor antagonists; Motor impairment; Hypothermia; Learning (Khanna, J.M. (230) 23)

**Excitatory amino acid**
Seizures; Nitric oxide (NO); Prepiriform cortex (deep); L-Arginine; Sodium nitroprusside (De Sarro, G. (230) 151)

**Excitatory amino acids**
Sensitization; Quisqualate priming; Cortical wedge; L-AP4 (L-2-amino-4-phosphonobutanoic acid) (Madsen, U. (230) 383)

**Eye**
Inflammation; Intraocular pressure; Eosinophils; Prostaglandin $D_2$; DP receptors (Woodward, D.F. (230) 327)

**Facilitation**
$\beta$-Adrenoceptors; Desensitization; Prejunctional; Stimulus train length (Lakhlani, P.P. (230) 107)

**Fetal breathing**
Opiates; $\delta$-Opioid receptors; [D-Ala$^2$]deltorphin; Naltrindole; Naloxonazine (Cheng, P.Y. (230) 85)

**Firing rate**
Galanin; Locus coeruleus neurons; Receptor interaction; Membrane potential (Sevcik, J. (230) 223)

**Flunitrazepam**
Development; Ethanol; $GABA_A$ receptors; Muscimol; Ro 15-4513 (Taira, T. (230) 307)

**Food intake**
Nitric oxide (NO); Brain; Zucker rat (Squadrito, F. (230) 125)

**$GABA_A$/benzodiazepine receptors**
Chlordiazepoxide; Passive avoidance response; Acetylcholine receptors; Autoradiography; Tolerance (Ishihara, S.-i. (230) 313)

**GABA receptors**
Distal colon; Enteric nerves; Gastrointestinal motility (Minocha, A. (230) 187)

**$GABA_A$ receptors**
Development; Ethanol; Flunitrazepam; Muscimol; Ro 15-4513 (Taira, T. (230) 307)

$\gamma$-Hydroxybutyric acid (GHB); Dopaminergic neurons; Ethanol; NMDA receptor antagonists (Diana, M. (230) 363)

**Galanin**
Locus coeruleus neurons; Receptor interaction; Firing rate; Membrane potential (Sevcik, J. (230) 223)

**Ganglion blockers**
Dequalinium; Sympathetic ganglia; Muscarinic receptor antagonists; Nicotinic receptor antagonists (Dunn, P.M. (230) 335)

**Gastrointestinal motility**
Distal colon; Enteric nerves; GABA receptors (Minocha, A. (230) 187)

**[$^3$H]GBR 12783 binding site occupancy**
Dopamine uptake inhibitors; Locomotor activity; Cytochrome P450; (Mouse) (Vaugeois, J.-M. (230) 195)

**Glibenclamide**
Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Gliquidone; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

**Glipizide, Tolbutamide**
Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Antinociception; Opiates (Ocaña, M. (230) 203)

**Gliquidone**
Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

**Glucose utilization**
Buspirone; Hippocampus; Lateral habenular nucleus; 1-PP (1-(2-pyrimidinyl)-piperazine); 2-Deoxyglucose (Grasby, P. (230) 41)

**Glutamate**
Dopamine; Neuroleptics; Nucleus accumbens; Corpus striatum; (Rat) (Bardgett, M.E. (230) 245)

**Glutamate receptors**
Phenobarbital; Dependence; Brain (Short, K.R. (230) 111)

**Haloperidol**
Dopamine; Electrooculogram; Light peak; Transepithelial potential; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Heart**
Atrium; Contractile force; 5-HT (5-hydroxytryptamine, serotonin); Ventricle; (Human) (Schoemaker, R.G. (230) 103)

**Heart rate**
Endothelin; Clonidine; Blood pressure; Medulla (ventral surface); (Sprague-Dawley rat) (Gulati, A. (230) 293)

**Hindlimb (isolated)**
5-HT (5-hydroxytryptamine, serotonin); Prostaglandins E; Temperature; Tachyphylaxis; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

**Hippocampus**
Buspirone; Glucose utilization; Lateral habenular nucleus; 1-PP (1-(2-pyrimidinyl)-piperazine); 2-Deoxyglucose (Grasby, P. (230) 41)

**Homovanillic acid (HVA)**
Milacemide; Amino acids; Monoamine metabolites; Taurine; Cerebrospinal fluid (Semba, J. (230) 321)

**5-HT (5-hydroxytryptamine, serotonin)**
Hindlimb (isolated); Prostaglandins E; Temperature; Tachyphylaxis; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

$5\text{-}HT_{1A}$ receptors; Raphe; S 15535; BMY 7378; NAN-190; Spiperone (Millan, M.J. (230) 99)

Atrium; Contractile force; Heart; Ventricle; (Human) (Schoemaker, R.G. (230) 103)

**$5\text{-}HT_3$ receptor antagonists**
Morphine; Mesolimbic dopamine; Microdialysis (Pei, Q. (230) 63)

**5-HT receptors**
LSD (d-lysergic acid diethylamide); Dissociation constant; Uterine artery (sheep) (Zhang, L. (230) 115)

**$5\text{-}HT_{1A}$ receptors**
5-HT (5-hydroxytryptamine, serotonin); Raphe; S 15535; BMY 7378; NAN-190; Spiperone (Millan, M.J. (230) 99)

**5-$HT_{1D}$ receptors**
5-Carboxamidotryptamine; Turning model; (Autoreceptor) (Moret, C. (230) 379)

**γ-Hydroxybutyric acid (GHB)**
$GABA_A$ receptors; Dopaminergic neurons; Ethanol; NMDA receptor antagonists (Diana, M. (230) 363)

**Hyperlocomotion**
Ceruletide; Amphetamine; Stereotypy; Microdialysis; (Rat) (Kihara, T. (230) 271)

**Hypertensive effect**
Endothelin-3; Big endothelin-3; Phosphoramidon; Metalloproteinase; (Conversion) (Matsumura, Y. (230) 89)

**Hypothermia**
(+)-MK-801; Ketamine; NMDA receptor antagonists; Ethanol tolerance; Motor impairment; Learning (Khanna, J.M. (230) 23)

**Imidazoline**
Islets of Langerhans; $K^+$ channels; $\alpha_2$-Adrenoceptors; RX851033; RX851034; RX821002 (Chan, S.L.F. (230) 375)

**Indomethacin**
Morphine; Naloxone; NANC (non-adrenergic, non-cholinergic); Small intestine; Vagal nerve (Gustafsson, B.I. (230) 1)

**Inflammation**
Eye; Intraocular pressure; Eosinophils; Prostaglandin $D_2$; DP receptors (Woodward, D.F. (230) 327)

**Interneurons**
NMDA receptor antagonists; Phencyclidine; Dizocilpine; σ Receptor ligands (Zhang, J. (230) 371)

**Intestinal absorption**
Digoxin; $Ca^{2+}$ channel blockers; (Guinea-pig) (Budihna, M.V. (230) 301)

**Intraocular pressure**
Eye; Inflammation; Eosinophils; Prostaglandin $D_2$; DP receptors (Woodward, D.F. (230) 327)

**[$^{123}$I]Iomazenil**
SPECT (single photon emission tomography); Benzodiazepine receptors (Laruelle, M. (230) 119)

**Islets of Langerhans**
$K^+$ channels; $\alpha_2$-Adrenoceptors; Imidazoline; RX851033; RX851034; RX821002 (Chan, S.L.F. (230) 375)

**$K^+$ channel activators**
Renal haemodynamics; Adrenoceptor agonists; Renal nerve stimulation (Johns, E.J. (230) 47)

**$K^+$ channel openers**
Arachidonic acid; Cytochrome P450 epoxygenase; Epoxyeicosatrienoic acid; Patch-clamp method; $K^+$ channels ($Ca^{2+}$-activated) (Hu, S. (230) 215)

**$K^+$ channels**
Islets of Langerhans; $\alpha_2$-Adrenoceptors; Imidazoline; RX851033; RX851034; RX821002 (Chan, S.L.F. (230) 375)

**$K^+$ channels (ATP-dependent)**
Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

**$K^+$ channels ($Ca^{2+}$-activated)**
Arachidonic acid; Cytochrome P450 epoxygenase; Epoxyeicosatrienoic acid; Patch-clamp method; $K^+$ channel openers (Hu, S. (230) 215)

**Ketamine**
(+)-MK-801; NMDA receptor antagonists; Ethanol tolerance; Motor impairment; Hypothermia; Learning (Khanna, J.M. (230) 23)

**Lateral habenular nucleus**
Buspirone; Glucose utilization; Hippocampus; 1-PP (1-(2-pyrimidinyl)-piperazine); 2-Deoxyglucose (Grasby, P. (230) 41)

**Learning**
(+)-MK-801; Ketamine; NMDA receptor antagonists; Ethanol tolerance; Motor impairment; Hypothermia (Khanna, J.M. (230) 23)

**Leukotrienes**
Cytokines; Endotoxin; cAMP (Schade, F.U. (230) 9)

**$Li^+$ clearance**
$Li^+$ reabsorption; $Na^+$ restriction; Amiloride (Shalmi, M. (230) 33)

**Lidocaine**
Use dependence; Acidosis; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (230) 167)

**Light peak**
Dopamine; Electrooculogram; Haloperidol; Transepithelial potential; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Lingual arteries (isolated)**
$\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; Phenylephrine; (Partial agonist) (Skrbic, R. (230) 131)

**$Li^+$ reabsorption**
$Na^+$ restriction; Amiloride; $Li^+$ clearance (Shalmi, M. (230) 33)

**Locomotor activity**
Dopamine uptake inhibitors; [$^3$H]GBR 12783 binding site occupancy; Cytochrome P450; (Mouse) (Vaugeois, J.-M. (230) 195)

**Locus coeruleus**
Primary neuronal cultures; Substantia nigra; κ-Opioid receptors; μ-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

**Locus coeruleus neurons**
Galanin; Receptor interaction; Firing rate; Membrane potential (Sevcik, J. (230) 223)

**Losartan**
Angiotensin II receptor subtypes; Cerebellum (human); Substantia nigra (human); Brain (human); [$^{125}$I]angiotensin II; PD123177 (Barnes, J.M. (230) 251)

**LSD (d-lysergic acid diethylamide)**
5-HT receptors; Dissociation constant; Uterine artery (sheep) (Zhang, L. (230) 115)

**Medulla (ventral surface)**
Endothelin; Clonidine; Blood pressure; Heart rate; (Sprague-Dawley rat) (Gulati, A. (230) 293)

**Membrane potential**
Galanin; Locus coeruleus neurons; Receptor interaction; Firing rate (Sevcik, J. (230) 223)

**Mesolimbic dopamine**
Morphine; 5-$HT_3$ receptor antagonists; Microdialysis (Pei, Q. (230) 63)

**Metalloproteinase**
Endothelin-3; Big endothelin-3; Hypertensive effect; Phosphoramidon; (Conversion) (Matsumura, Y. (230) 89)

**Methamphetamine**
$\sigma$ Receptors; Psychosis (Itzhak, Y. (230) 243)

**Microdialysis**
Morphine; Mesolimbic dopamine; 5-$HT_3$ receptor antagonists (Pei, Q. (230) 63)

Neurotensin; CCK-8 (cholecystokinin-8); Receptor–receptor interaction; Dopamine $D_2$ receptors; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

Ceruletide; Amphetamine; Hyperlocomotion; Stereotypy; (Rat) (Kihara, T. (230) 271)

**Milacemide**
Amino acids; Monoamine metabolites; Taurine; Homovanillic acid (HVA); Cerebrospinal fluid (Semba, J. (230) 321)

**(+)-MK-801**
Ketamine; NMDA receptor antagonists; Ethanol tolerance; Motor impairment; Hypothermia; Learning (Khanna, J.M. (230) 23)

**MK-801**
Temperature dependence; Repetitive firing (sustained); $Na^+$-dependent action potentials; Neurons (cultured) (Wamil, A.W. (230) 263)

**Monoamine metabolites**
Milacemide; Amino acids; Taurine; Homovanillic acid (HVA); Cerebrospinal fluid (Semba, J. (230) 321)

**Morphine**
Indomethacin; Naloxone; NANC (non-adrenergic, non-cholinergic); Small intestine; Vagal nerve (Gustafsson, B.I. (230) 1)

Mesolimbic dopamine; 5-$HT_3$ receptor antagonists; Microdialysis (Pei, Q. (230) 63)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Conditioned place preference; Naloxone; Addiction; (Mouse) (Noble, F. (230) 139)

U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

**Motor deficits**
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Substantia nigra; Dopamine; Age; (Common marmoset) (Rose, S. (230) 177)

**Motor impairment**
(+)-MK-801; Ketamine; NMDA receptor antagonists; Ethanol tolerance; Hypothermia; Learning (Khanna, J.M. (230) 23)

**MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)**
Substantia nigra; Motor deficits; Dopamine; Age; (Common marmoset) (Rose, S. (230) 177)

**Mucosa**
AIDS; Cytokine; T lymphocytes; Virus infection (Bourinbaiar, A.S. (230) 15)

**Muscarinic receptor antagonists**
Dequalinium; Sympathetic ganglia; Ganglion blockers; Nicotinic receptor antagonists (Dunn, P.M. (230) 335)

**Muscimol**
Development; Ethanol; Flunitrazepam; $GABA_A$ receptors; Ro 15-4513 (Taira, T. (230) 307)

**Myometrium**
Cervical smooth muscle; Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$); Pregnancy; Electrical field stimulation (Okawa, T. (230) 341)

**$Na^+$-dependent action potentials**
Temperature dependence; MK-801; Repetitive firing (sustained); Neurons (cultured) (Wamil, A.W. (230) 263)

**Naloxonazine**
Fetal breathing; Opiates; $\delta$-Opioid receptors; [D-$Ala^2$]deltorphin; Naltrindole (Cheng, P.Y. (230) 85)

**Naloxone**
Indomethacin; Morphine; NANC (non-adrenergic, non-cholinergic); Small intestine; Vagal nerve (Gustafsson, B.I. (230) 1)

RB101 (mixed inhibitor of enkephalin-degrading enzymes); Morphine; Conditioned place preference; Addiction; (Mouse) (Noble, F. (230) 139)

**Naltrindole**
Fetal breathing; Opiates; $\delta$-Opioid receptors; [D-$Ala^2$]deltorphin; Naloxonazine (Cheng, P.Y. (230) 85)

**NAN-190**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; Raphe; S 15535; BMY 7378; Spiperone (Millan, M.J. (230) 99)

**NANC (non-adrenergic, non-cholinergic)**
Indomethacin; Morphine; Naloxone; Small intestine; Vagal nerve (Gustafsson, B.I. (230) 1)

**$Na^+$ restriction**
$Li^+$ reabsorption; Amiloride; $Li^+$ clearance (Shalmi, M. (230) 33)

**Neostriatum**
Neurotensin; CCK-8 (cholecystokinin-8); Receptor–receptor interaction; Dopamine $D_2$ receptors; Microdialysis; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

**Neuroleptics**
Glutamate; Dopamine; Nucleus accumbens; Corpus striatum; (Rat) (Bardgett, M.E. (230) 245)

**Neurological examination**
Cerebral ischemia (focal); Riluzole; Passive avoidance task; (Rat) (Wahl, F. (230) 209)

**Neurons (cultured)**
Temperature dependence; MK-801; Repetitive firing (sustained); $Na^+$-dependent action potentials (Wamil, A.W. (230) 263)

**Neurotensin**
CCK-8 (cholecystokinin-8); Receptor–receptor interaction; Dopamine $D_2$ receptors; Microdialysis; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

**Nicotinic receptor antagonists**
Dequalinium; Sympathetic ganglia; Ganglion blockers; Muscarinic receptor antagonists (Dunn, P.M. (230) 335)

**Nicotinic receptors**
Cobalt ramps; Adrenal medulla; Catecholamine secretion (Montiel, C. (230) 77)

**Nitric oxide (NO)**
Brain; Food intake; Zucker rat (Squadrito, F. (230) 125)

Seizures; Prepiriform cortex (deep); Excitatory amino acid; L-Arginine; Sodium nitroprusside (De Sarro, G. (230) 151)

**NMDA (N-methyl-D-aspartate)**
Primary neuronal cultures; Substantia nigra; Locus coeruleus; $\kappa$-Opioid receptors; $\mu$-Opioid receptors (Ronken, E. (230) 349)

**NMDA receptor antagonists**
(+)-MK-801; Ketamine; Ethanol tolerance; Motor impairment; Hypothermia; Learning (Khanna, J.M. (230) 23)

Drug discrimination; NPC 12626; CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); CGP 37849; Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

$\gamma$-Hydroxybutyric acid (GHB); $GABA_A$ receptors; Dopaminergic neurons; Ethanol (Diana, M. (230) 363)

Phencyclidine; Dizocilpine; $\sigma$ Receptor ligands; Interneurons (Zhang, J. (230) 371)

**[$^3$H]Noradrenaline release**
NPY receptors; Brain; Terminals; (Rat) (Martire, M. (230) 231)

**Noxious**
Opioids; Parabrachial; Thermal stimuli; Pain pathway; Analgesia; (Rat) (Huang, G.-F. (230) 279)

**NPC 12626**
Drug discrimination; NMDA receptor antagonists; CPPene (D-3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid); CGP 37849; Dizocilpine; (Squirrel monkey) (Gold, L.H. (230) 285)

**NPY receptors**
Brain; Terminals; [$^3$H]Noradrenaline release; (Rat) (Martire, M. (230) 231)

**Nucleus accumbens**
Glutamate; Dopamine; Neuroleptics; Corpus striatum; (Rat) (Bardgett, M.E. (230) 245)

**Opiates**
Fetal breathing; $\delta$-Opioid receptors; [D-Ala$^2$]deltorphin; Naltrindole; Naloxonazine (Cheng, P.Y. (230) 85)

Morphine; U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide); $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Antinociception (Ocaña, M. (230) 203)

**Opioid receptor antagonists**
Antinociception; $\mu$-Opioid receptors (Jiang, Q. (230) 129)

**Opioid receptors**
Deltorphin; Peptide synthesis; Computer modelling (Salvadori, S. (230) 357)

**$\delta$-Opioid receptors**
Fetal breathing; Opiates; [D-Ala$^2$]deltorphin; Naltrindole; Naloxonazine (Cheng, P.Y. (230) 85)

Dopamine; Ethanol (Acquas, E. (230) 239)

**$\kappa$-Opioid receptors**
Primary neuronal cultures; Substantia nigra; Locus coeruleus; $\mu$-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

**$\mu$-Opioid receptors**
Antinociception; Opioid receptor antagonists (Jiang, Q. (230) 129)

Primary neuronal cultures; Substantia nigra; Locus coeruleus; $\kappa$-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

**Opioids**
Receptor subtypes; $Cl^-$ secretion (intestinal) (Kromer, W. (230) 235)

Parabrachial; Noxious; Thermal stimuli; Pain pathway; Analgesia; (Rat) (Huang, G.-F. (230) 279)

**Pain pathway**
Opioids; Parabrachial; Noxious; Thermal stimuli; Analgesia; (Rat) (Huang, G.-F. (230) 279)

**Parabrachial**
Opioids; Noxious; Thermal stimuli; Pain pathway; Analgesia; (Rat) (Huang, G.-F. (230) 279)

**Parkinson's disease**
Dopamine; Electrooculogram; Haloperidol; Light peak; Transepithelial potential; Retina; (Chicken) (Rudolf, G. (230) 259)

**Passive avoidance response**
Chlordiazepoxide; $GABA_A$/benzodiazepine receptors; Acetylcholine receptors; Autoradiography; Tolerance (Ishihara, S.-i. (230) 313)

**Passive avoidance task**
Cerebral ischemia (focal); Riluzole; Neurological examination; (Rat) (Wahl, F. (230) 209)

**Patch-clamp method**
Arachidonic acid; Cytochrome P450 epoxygenase; Epoxyeicosatrienoic acid; $K^+$ channels ($Ca^{2+}$-activated); $K^+$ channel openers (Hu, S. (230) 215)

**PD123177**
Angiotensin II receptor subtypes; Cerebellum (human); Substantia nigra (human); Brain (human); [$^{125}$I]angiotensin II; Losartan (Barnes, J.M. (230) 251)

**Peptide synthesis**
Deltorphin; Opioid receptors; Computer modelling (Salvadori, S. (230) 357)

**Pertussis toxin**
Angiotensin II; Cholera toxin; Portal vein (rat); Dibutyryl cAMP (Zhang, J. (230) 95)

**Phencyclidine**
NMDA receptor antagonists; Dizocilpine; $\sigma$ Receptor ligands; Interneurons (Zhang, J. (230) 371)

**Phenobarbital**
Dependence; Glutamate receptors; Brain (Short, K.R. (230) 111)

**Phenylephrine**
Lingual arteries (isolated); $\alpha_1$-Adrenoceptors; $\alpha_2$-Adrenoceptors; (Partial agonist) (Skrbic, R. (230) 131)

**Phosphoramidon**
Endothelin-3; Big endothelin-3: Hypertensive effect; Metalloproteinase; (Conversion) (Matsumura, Y. (230) 89)

**Portal vein (rat)**
Angiotensin II; Cholera toxin; Pertussis toxin; Dibutyryl cAMP (Zhang, J. (230) 95)

**1-PP (1-(2-pyrimidinyl)-piperazine)**
Buspirone; Glucose utilization; Hippocampus; Lateral habenular nucleus; 2-Deoxyglucose (Grasby, P. (230) 41)

**Pregnancy**
Myometrium; Cervical smooth muscle; Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$); Electrical field stimulation (Okawa, T. (230) 341)

**Prejunctional**
$\beta$-Adrenoceptors; Desensitization; Facilitation; Stimulus train length (Lakhlani, P.P. (230) 107)

**Prepiriform cortex (deep)**
Seizures; Nitric oxide (NO); Excitatory amino acid; L-Arginine; Sodium nitroprusside (De Sarro, G. (230) 151)

**Primary neuronal cultures**
Substantia nigra; Locus coeruleus; $\kappa$-Opioid receptors; $\mu$-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

**Prostaglandin $D_2$**
Eye; Inflammation; Intraocular pressure; Eosinophils; DP receptors (Woodward, D.F. (230) 327)

**Prostaglandins E**
5-HT (5-hydroxytryptamine, serotonin); Hindlimb (isolated); Temperature; Tachyphylaxis; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

**Prostaglandins ($PGE_2$, $PGI_2$ and $PGF_{2\alpha}$)**
Myometrium; Cervical smooth muscle; Pregnancy; Electrical field stimulation (Okawa, T. (230) 341)

**Psychosis**
Methamphetamine; $\sigma$ Receptors (Itzhak, Y. (230) 243)

**Purkinje fibers**
Lidocaine; Use dependence; Acidosis; Electrophysiology (developmental) (Hamra, M. (230) 167)

**Quisqualate priming**
Excitatory amino acids; Sensitization; Cortical wedge; L-AP4 (L-2-amino-4-phosphonobutanoic acid) (Madsen, U. (230) 383)

**Raphe**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; S 15535; BMY 7378; NAN-190; Spiperone (Millan, M.J. (230) 99)

**RB101 (mixed inhibitor of enkephalin-degrading enzymes)**
Morphine; Conditioned place preference; Naloxone; Addiction; (Mouse) (Noble, F. (230) 139)

**Receptor interaction**
Galanin; Locus coeruleus neurons; Firing rate; Membrane potential (Sevcik, J. (230) 223)

**$\sigma$ Receptor ligands**
NMDA receptor antagonists; Phencyclidine; Dizocilpine; Interneurons (Zhang, J. (230) 371)

**Receptor–receptor interaction**
Neurotensin; CCK-8 (cholecystokinin-8); Dopamine $D_2$ receptors; Microdialysis; Neostriatum; (Receptor binding); (Rat) (Tanganelli, S. (230) 159)

**$\sigma$ Receptors**
Methamphetamine; Psychosis (Itzhak, Y. (230) 243)

**Receptor subtypes**
Opioids; $Cl^-$ secretion (intestinal) (Kromer, W. (230) 235)

**Renal haemodynamics**
$K^+$ channel activators; Adrenoceptor agonists; Renal nerve stimulation (Johns, E.J. (230) 47)

**Renal nerve stimulation**
$K^+$ channel activators; Renal haemodynamics; Adrenoceptor agonists (Johns, E.J. (230) 47)

**Repetitive firing (sustained)**
Temperature dependence; MK-801; $Na^+$-dependent action potentials; Neurons (cultured) (Wamil, A.W. (230) 263)

**Retina**
Dopamine; Electrooculogram; Haloperidol; Light peak; Transepithelial potential; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Riluzole**
Cerebral ischemia (focal); Neurological examination; Passive avoidance task; (Rat) (Wahl, F. (230) 209)

**Ro 15-4513**
Development; Ethanol; Flunitrazepam; $GABA_A$ receptors; Muscimol (Taira, T. (230) 307)

**RX821002**
Islets of Langerhans; $K^+$ channels; $\alpha_2$-Adrenoceptors; Imidazoline; RX851033; RX851034 (Chan, S.L.F. (230) 375)

**RX851033**
Islets of Langerhans; $K^+$ channels; $\alpha_2$-Adrenoceptors; Imidazoline; RX851034; RX821002 (Chan, S.L.F. (230) 375)

**RX851034**
Islets of Langerhans; $K^+$ channels; $\alpha_2$-Adrenoceptors; Imidazoline; RX851033; RX821002 (Chan, S.L.F. (230) 375)

**Ryanodine**
Thapsigargin; Smooth muscle (vascular); $Ca^{2+}$ mobilization (Low, A.M. (230) 53)

**S 15535**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; Raphe; BMY 7378; NAN-190; Spiperone (Millan, M.J. (230) 99)

**Seizures**
Nitric oxide (NO); Prepiriform cortex (deep); Excitatory amino acid; L-Arginine; Sodium nitroprusside (De Sarro, G. (230) 151)

**Sensitization**
Excitatory amino acids; Quisqualate priming; Cortical wedge; L-AP4 (L-2-amino-4-phosphonobutanoic acid) (Madsen, U. (230) 383)

**Small intestine**
Indomethacin; Morphine; Naloxone; NANC (non-adrenergic, non-cholinergic); Vagal nerve (Gustafsson, B.I. (230) 1)

**Smooth muscle (vascular)**
Thapsigargin; Ryanodine; $Ca^{2+}$ mobilization (Low, A.M. (230) 53)

**Sodium nitroprusside**
Seizures; Nitric oxide (NO); Prepiriform cortex (deep); Excitatory amino acid; L-Arginine (De Sarro, G. (230) 151)

**SPECT (single photon emission tomography)**
[$^{123}$I]Iomazenil; Benzodiazepine receptors (Laruelle, M. (230) 119)

**Spiperone**
5-HT (5-hydroxytryptamine, serotonin); 5-$HT_{1A}$ receptors; Raphe; S 15535; BMY 7378; NAN-190 (Millan, M.J. (230) 99)

**Stereotypy**
Ceruletide; Amphetamine; Hyperlocomotion; Microdialysis; (Rat) (Kihara, T. (230) 271)

**Stimulus train length**
$\beta$-Adrenoceptors; Desensitization; Facilitation; Prejunctional (Lakhlani, P.P. (230) 107)

**Substance P**
Tracheal epithelium; Thrombin; Endothelin; Vasopressin (Rennick, R.E. (230) 367)

**Substantia nigra**
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Motor deficits; Dopamine; Age; (Common marmoset) (Rose, S. (230) 177)

Primary neuronal cultures; Locus coeruleus; $\kappa$-Opioid receptors; $\mu$-Opioid receptors; NMDA (N-methyl-D-aspartate) (Ronken, E. (230) 349)

**Substantia nigra (human)**
Angiotensin II receptor subtypes; Cerebellum (human); Brain (human); [$^{125}$I]angiotensin II; Losartan; PD123177 (Barnes, J.M. (230) 251)

**Sympathetic ganglia**
Dequalinium; Ganglion blockers; Muscarinic receptor antagonists; Nicotinic receptor antagonists (Dunn, P.M. (230) 335)

**Tachyphylaxis**
5-HT (5-hydroxytryptamine, serotonin); Hindlimb (isolated); Prostaglandins E; Temperature; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

**Taurine**
Milacemide; Amino acids; Monoamine metabolites; Homovanillic acid (HVA); Cerebrospinal fluid (Semba, J. (230) 321)

**Temperature**
5-HT (5-hydroxytryptamine, serotonin); Hindlimb (isolated); Prostaglandins E; Tachyphylaxis; Vasoconstriction; (Release) (Rat) (Šmíd, M. (230) 69)

**Temperature dependence**
MK-801; Repetitive firing (sustained); $Na^+$-dependent action potentials; Neurons (cultured) (Wamil, A.W. (230) 263)

**Terminals**
NPY receptors; Brain; [$^3$H]Noradrenaline release; (Rat) (Martire, M. (230) 231)

**Thapsigargin**
Ryanodine; Smooth muscle (vascular); $Ca^{2+}$ mobilization (Low, A.M. (230) 53)

**Thermal stimuli**
Opioids; Parabrachial; Noxious; Pain pathway; Analgesia; (Rat) (Huang, G.-F. (230) 279)

**Thrombin**
Tracheal epithelium; Endothelin; Vasopressin; Substance P (Rennick, R.E. (230) 367)

**T lymphocytes**
AIDS; Cytokine; Mucosa; Virus infection (Bourinbaiar, A.S. (230) 15)

**Tolerance**
Chlordiazepoxide; Passive avoidance response; $GABA_A$/benzodiazepine receptors; Acetylcholine receptors; Autoradiography (Ishihara, S.-i. (230) 313)

**Tracheal epithelium**
Thrombin; Endothelin; Vasopressin; Substance P (Rennick, R.E. (230) 367)

**Transepithelial potential**
Dopamine; Electrooculogram; Haloperidol; Light peak; Retina; Parkinson's disease; (Chicken) (Rudolf, G. (230) 259)

**Turning model**
5-$HT_{1D}$ receptors; 5-Carboxamidotryptamine; (Autoreceptor) (Moret, C. (230) 379)

**U-504,88H (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzeneacetamide)**
Morphine; $K^+$ channels (ATP-dependent); Glibenclamide; Gliquidone; Glipizide, Tolbutamide; Antinociception; Opiates (Ocaña, M. (230) 203)

**Use dependence**
Lidocaine; Acidosis; Electrophysiology (developmental); Purkinje fibers (Hamra, M. (230) 167)

**Uterine artery (sheep)**
LSD (d-lysergic acid diethylamide); 5-HT receptors; Dissociation constant (Zhang, L. (230) 115)

**Vagal nerve**
Indomethacin; Morphine; Naloxone; NANC (non-adrenergic, non-cholinergic); Small intestine (Gustafsson, B.I. (230) 1)

**Vasoconstriction**
5-HT (5-hydroxytryptamine, serotonin); Hindlimb (isolated); Prostaglandins E; Temperature; Tachyphylaxis; (Release) (Rat) (Šmíd, M. (230) 69)

**Vasopressin**
Tracheal epithelium; Thrombin; Endothelin; Substance P (Rennick, R.E. (230) 367)

**Ventricle**
Atrium; Contractile force; Heart; 5-HT (5-hydroxytryptamine, serotonin); (Human) (Schoemaker, R.G. (230) 103)

**Virus infection**
AIDS; Cytokine; T lymphocytes; Mucosa (Bourinbaiar, A.S. (230) 15)

**Zucker rat**
Nitric oxide (NO); Brain; Food intake (Squadrito, F. (230) 125)